Repurposing therapies in junctional epidermolysis bullosa: ivermectin may influence RNA splicing and improve functional protein expression

Clinical images of subject patient's lower limbs demonstrating improved wound re-epithelialisation with continued oral ivermectin therapy from February 2021 (Fig. 1), after four months of therapy in June 2021 (Fig. 2), and after one year of therapy in April 2022 (Fig. 3).

本数据集收录了受试者患者下肢的临床影像，用以展示持续口服伊维菌素治疗期间伤口再上皮化的改善进程：2021年2月启动治疗时（图1）、治疗四个月后的2021年6月（图2），以及治疗满一年后的2022年4月（图3）。